Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2007

View Archived Issues

HDL mimetic CSL-111 shown to reduce atherosclerotic burden in the ERASE trial

Valortim demonstrates therapeutic effect in new primate model of anthrax

Plant-derived vaccine adjuvant shows enhanced immune response against hepatitis B in mice

Avanir provides business update

Phase II study of incyclinide in acne studies 40 mg dose

PRX-00023 studied in new phase IIb trial for major depressive disorder

FDA requires additional phase III study for cintredekin besudotox

Phase I/II data for Baxter's adjuvant-free pandemic H5N1 influenza vaccine

Hollis-Eden files IND to begin clinical testing of HE-3286 for metabolic disorders

European orphan drug status for Elafin

Udenafil demonstrates efficacy in erectile dysfunction phase IIb study

Structure and biological evaluation of CKD-501 presented at the ACS meeting

Novel glucocorticoid receptor modulator profiled at Merck

Provenge recommended for approval for prostate cancer

New data presented for bifeprunox

CanBas and Takeda collaborate in cancer

Aska licenses rights to JCR's recombinant FSH

PC-190708: a novel DNA gyrase B inhibitor identified at Prolysis

New agents for treating extrapyramidal disorders disclosed in recent Kissei patents

Recent patents report novel therapeutic agents for metabolic disorders

Recent Pfizer patent discloses new treatments for attention deficit hyperactivity disorder

Ceprotin approved for severe congenital protein C deficiency

Novartis suspends U.S. sales of Zelnorm

Janumet receives FDA approval

Lapatinib filed for approval in Japan for advanced breast cancer

Abbott seeks U.S. and E.U. approval of Humira for chronic plaque psoriasis

Twinrix approved for new accelerated dosing schedule

Exjade filed in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...